Literature DB >> 1623910

The pharmacokinetics of fluconazole during haemodialysis in uraemic patients.

S Oono1, K Tabei, T Tetsuka, Y Asano.   

Abstract

We have studied the pharmacokinetics of fluconazole in five patients on long-term haemodialysis. The single-pass extraction rate of the dialyzer was 59 (3.5)% (n = 4), and the serum concentration was reduced by haemodialysis for 3 or 4 h by 26 (3.2)% (n = 5) and 39 (2.2)% (n = 9) respectively. The estimated amount extracted by a dialysis of 4 h was 33 (3.2)% (n = 4) of the dose. During repeated administration the serum fluconazole concentration increased, reaching a plateau at about 4 times the peak concentration after the first dose. After discontinuing administration the serum fluconazole concentration fell by 25% in every 3 h dialysis session. We conclude that fluconazole should be given in the usual dose of 100 or 200 mg at the end of every haemodialysis session.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623910     DOI: 10.1007/bf00265934

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Cryptococcal meningitis and fluconazole.

Authors:  B Dupont; E Drouhet
Journal:  Ann Intern Med       Date:  1987-05       Impact factor: 25.391

2.  Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

Authors:  M J Humphrey; S Jevons; M H Tarbit
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Gas chromatographic method for the determination of fluconazole, a novel antifungal agent, in human plasma and urine.

Authors:  P R Wood; M H Tarbit
Journal:  J Chromatogr       Date:  1986-11-28

4.  Endotoxin-inactivating activity in normal and pathological human blood samples.

Authors:  T Obayashi; H Tamura; S Tanaka; M Ohki; S Takahashi; T Kawai
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

5.  [Clinical study of fluconazole on deep-seated fungal infections].

Authors:  H Ikemoto; K Watanabe; T Mori; A Taniuchi; Y Akahonai; C Mikuni; K Yoshida; M Kasai; K Kawamura; T Yoshida
Journal:  Jpn J Antibiot       Date:  1989-01
  5 in total
  5 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Elimination of fluconazole during continuous veno-venous haemodialysis (CVVHD) in a single patient.

Authors:  K Wolter; G Marggraf; H Dermoumi; E Fritschka
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

Review 5.  Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis.

Authors:  Christo Cimino; Yvonne Burnett; Nikunj Vyas; Anne H Norris
Journal:  Drugs       Date:  2021-02-16       Impact factor: 11.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.